Nektar Therapeutics (LTS:0UNL) Other Long-Term Liabilities : $93.08 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Nektar Therapeutics Other Long-Term Liabilities?

Nektar Therapeutics's other long-term liabilities for the quarter that ended in Mar. 2025 was $93.08 Mil.

Nektar Therapeutics's quarterly other long-term liabilities declined from Sep. 2024 ($104.74 Mil) to Dec. 2024 ($99.02 Mil) and declined from Dec. 2024 ($99.02 Mil) to Mar. 2025 ($93.08 Mil).

Nektar Therapeutics's annual other long-term liabilities declined from Dec. 2022 ($162.93 Mil) to Dec. 2023 ($117.26 Mil) and declined from Dec. 2023 ($117.26 Mil) to Dec. 2024 ($99.02 Mil).

Nektar Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Nektar Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Other Long-Term Liabilities Chart

Nektar Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

209.32

226.75

162.93

117.26

99.02

Nektar Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															122.19	115.56	104.74	99.02	93.08

Nektar Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Nektar Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

NKTR:USA ITH:Germany ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Nektar Therapeutics Headlines

No Headlines